Author

J. A. Katzenellenbogen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

J. C. Nwachukwu· 3 shared K. W. Nettles· 3 shared S. H. Kim· 3 shared B. S. Katzenellenbogen· 2 shared J. Min· 2 shared R. Houtman· 2 shared T. Izard· 2 shared Y. Hou· 2 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. C. Nwachukwu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Asymmetric Allostery in Estrogen Receptor-α Homodimers Drives Responses to the Ensemble of Estrogens in the Hormonal Milieu

C. K. Min, J. C. Nwachukwu, Y. Hou, R. Russo, A. Papa, J. Min, R. Peng, S. H. Kim, Y. Zeigler, E. S. Rangarajan, T. Izard, B. S. Katzenellenbogen, J. A. Katzenellenbogen, K. W. Nettles

This paper shows that estrogen receptor-α homodimers can function as conformational heterodimers, integrating different ligand signals to produce distinct agonist or antagonist activity profiles.

bioRxiv · Apr 10, 2024 · PreprintBiophysics

CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production

M. Doepner, C. A. Natale, I. Y. Lee, S. Venkat, S. H. Kim, J. A. Katzenellenbogen, B. S. Katzenellenbogen, M. Feigin, T. W. Ridky

This study identifies CHRM1 as a druggable melanoma target influenced by genetic variation in DOPA production, showing DOPA inhibits CHRM1 to suppress melanoma proliferation.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Dual mechanism estrogen receptor inhibitors

J. Min, J. C. Nwachukwu, S. Srinivasan, E. Rangarajan, C. C. Nettles, V. Sanabria Guillen, Y. Ziegler, S. Yan, K. Carlson, Y. Hou, S. H. Kim, S. Novick, B. Pascal, R. Houtman, P. Griffin, , K. W. Nettles

This paper develops dual-mechanism ER inhibitors that use two distinct targeting moieties to suppress ER activity in breast cancer cells and resistance models.

bioRxiv · Jul 6, 2020Cancer Biology

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells

S. W. Fanning, R. Jeselsohn, V. Dharmarajan, C. G. Mayne, M. Karimi, G. Buchwalter, R. Houtman, W. Toy, C. E. Fowler, M. Laine, K. E. Carlson, T. A. Martin, J. Nowak, J. C. Nwachukwu, D. J. Hosfield, , G. L. Greene

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.

bioRxiv · Apr 23, 2018Cancer Biology